Wellbeing Digital Sciences announced that subsidiary KGK Sciences applied for a phase 2A microdose psilocybin trial for fragile X syndrome for its client, Nova Mentis Life Science.
Nova has produced 1.5 mg psilocybin microdose capsules. These capsules were produced according to defined manufacturing processes and product specifications as outlined in chemistry, manufacturing, and controls (CMC) published guidelines.